공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

ACLF(Acute On Chronic Liver Failure) 시장 : 인사이트, 역학, 예측(-2030년)

Acute On Chronic Liver Failure (ACLF) Market Insight, Epidemiology and Market Forecast -2030

리서치사 DelveInsight Business Research LLP
발행일 On Demand Report 상품 코드 968236
페이지 정보 영문 200 Pages
가격
US $ 6,950 ₩ 8,073,000 PDF (Single User License)
US $ 13,900 ₩ 16,146,000 PDF (Site License)
US $ 20,850 ₩ 24,219,000 PDF (Global License)


ACLF(Acute On Chronic Liver Failure) 시장 : 인사이트, 역학, 예측(-2030년) Acute On Chronic Liver Failure (ACLF) Market Insight, Epidemiology and Market Forecast -2030
발행일 : On Demand Report 페이지 정보 : 영문 200 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 주요 7개국(미국, 유럽 5개국(독일, 스페인, 이탈리아, 프랑스 및 영국), 일본)의 ACLF(Acute On Chronic Liver Failure) 시장 규모는 조사 기간 중(2017-2030년) 대폭적인 CAGR로 증가할 것으로 예측됩니다. 미국 시장은 최대 규모입니다. 또한 유럽 5개국 중에서는 독일의 시장 규모가 최대이며, 1,793만 달러(2017년)에 달했습니다. 한편, 이탈리아의 시장 규모는 최소로 180만 달러였습니다.

세계 주요 7개국의 2017년 ACLF(Acute On Chronic Liver Failure) 총환자 수는 6만 521명이었습니다. 이 증례는 조사 기간 중(2017-2030) 대폭적인 CAGR로 증가할 것으로 예측됩니다.

세계 주요 7개국(미국, 유럽 5개국(독일, 스페인, 이탈리아, 프랑스 및 영국), 일본)의 ACLF(Acute On Chronic Liver Failure) 시장에 대해 조사했으며, 역학, 시장 규모 및 예측, 성장요인 및 과제, 치료법·국가별 시장 분석, 주요 기업의 제품 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 인사이트

제2장 개요

제3장 SWOT 분석

제4장 ACLF 역학의 개요

  • 2017년 ACLF의 환자 점유율 분포
  • 2030년 ACLF의 환자 점유율 분포

제5장 ACLF 시장의 개요

  • 2017년 ACLF의 시장 점유율 분포
  • 2030년 ACLF의 시장 점유율 분포

제6장 질환 배경과 개요

  • 서론
  • 정의의 불균일성
  • ACLF의 유형
  • 임상적 특징과 병태생리학
  • ACLF의 진단
  • ACLF 바이오마커

제7장 국가별 역학

  • 전제조건과 이론적 근거 : 주요 7개국

제8장 역학과 환자 인구

  • 주요 조사 결과
  • 미국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
  • 일본

제9장 치료

  • 가이드라인
    • APASL
    • 비대상성 간경변 환자의 관리를 위한 EASL 진료 가이드라인
  • 사례 연구
    • ACLF(Acute On Chronic Liver Failure)와 기존 급성 비대상성 간경변의 비교
  • 치료 여정

제10장 미충족 요구

제11장 새로운 치료법

  • Albutein(PE-A 5%): Grifols Therapeutics
    • 제품 설명
    • 임상 개발
  • HepaStem : Promethera Biosciences
    • 기타 개발 활동
    • 안전성과 유효성

제12장 기타 유망한 치료법 후보

  • APZ2 : RHEACELL
    • 제품 설명
    • 임상 개발
  • VS-01 : Versantis
    • 기타 개발 활동
  • Livantra: Martin Pharmaceuticals
    • 기타 개발 활동

제13장 주요 7개국의 시장 분석

  • 주요 조사 결과
  • 주요 7개국의 시장 규모
  • 시장 전망 : 주요 7개국

제14장 국가별 시장 분석

  • 미국
    • 전체 시장 규모
    • 치료별 시장 규모
  • 유럽 5개국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국
  • 일본

제15장 시장 성장요인

제16장 시장 장벽

제17장 부록

  • 리포트 조사 방법

제18장 DelveInsight의 서비스 내용

제19장 면책사항

제20장 DelveInsight 소개

KSA 20.11.17

List of Tables

  • Table 1: Summary of ACLF Market, Epidemiology, and Key Events (2018-2030)
  • Table 2: Organization Contributing towards acute-on-chronic liver failure (ACLF)
  • Table 3: Characteristics of the available definitions for acute-on-chronic liver failure (ACLF)
  • Table 4: CLIF Consortium Organ Failure Score: simplified version of the CLIF-SOFA score
  • Table 5: Total Prevalent Patient Population of Acute-on-chronic liver failure (2018-2030)
  • Table 6: Cases of ACLF in the US 2018-2030)
  • Table 7: Cases of ACLF by Grades in the US (2018-2030)
  • Table 8: Organ failures associated with ACLF in the United States (2018-2030)
  • Table 9: Potential precipitating events of ACLF in the US (2018-2030)
  • Table 10: Cases of ACLF in Germany (2018-2030)
  • Table 11: Cases of ACLF by Grades in Germany (2018-2030)
  • Table 12: Organ failures associated with ACLF in Germany (2018-2030)
  • Table 13: Potential precipitating events of ACLF in Germany (2018-2030)
  • Table 14: Cases of ACLF in France (2018-2030)
  • Table 15: Cases of ACLF by Grades in France (2018-2030)
  • Table 16: Organ failures associated with ACLF in France (2018-2030)
  • Table 17: Potential precipitating events of ACLF in France (2018-2030)
  • Table 18: Cases of ACLF in Italy (2018-2030)
  • Table 19: Cases of ACLF by Grades in Italy (2018-2030)
  • Table 20: Organ failures associated with ACLF in Italy (2018-2030)
  • Table 21: Potential precipitating events of ACLF in Italy (2018-2030)
  • Table 22: Cases of ACLF in Spain (2018-2030)
  • Table 23: Cases of ACLF by Grades in Spain (2018-2030)
  • Table 24: Organ failures associated with ACLF in Spain (2018-2030)
  • Table 25: Potential precipitating events of ACLF in Spain (2018-2030)
  • Table 26: Cases of ACLF in the UK (2018-2030)
  • Table 27: Cases of ACLF by Grades in the UK (2018-2030)
  • Table 28: Organ failures associated with ACLF in the UK (2018-2030)
  • Table 29: Potential precipitating events of ACLF in the UK (2018-2030)
  • Table 30: Cases of ACLF in the UK (2018-2030)
  • Table 31: Cases of ACLF by Grades in Japan (2018-2030)
  • Table 32: Organ failures associated with ACLF in Japan (2018-2030)
  • Table 33: Potential precipitating events of ACLF in Japan (2018-2030)
  • Table 34: PE-A 5%, Clinical Trial Description, 2021
  • Table 35: HepaStem, Clinical Trial Description, 2021
  • Table 36: HepaStem, Clinical Trial Description, 2021
  • Table 37: 7 Major Market Size of Acute-on-chronic liver failure, USD Millions (2018-2030)
  • Table 38: The US Market Size of Acute-on-chronic liver failure, USD Millions (2018-2030)
  • Table 39: US market size of Acute-on-chronic liver failure by therapies in USD Million (2018-2030)
  • Table 40: Germany Market Size of Acute-on-chronic liver failure, USD Millions (2018-2030)
  • Table 41: Germany market size of Acute-on-chronic liver failure by therapies in USD Million (2018-2030)
  • Table 42: France Market Size of Acute-on-chronic liver failure, USD Millions (2018-2030)
  • Table 43: France market size of Acute-on-chronic liver failure by therapies in USD Million (2018-2030)
  • Table 44: Italy Market Size of Acute-on-chronic liver failure, USD Millions (2018-2030)
  • Table 45: Italy market size of Acute-on-chronic liver failure by therapies in USD Million (2018-2030)
  • Table 46: Spain Market Size of Acute-on-chronic liver failure, USD Millions (2018-2030)
  • Table 47: Spain market size of Acute-on-chronic liver failure by therapies in USD Million (2018-2030)
  • Table 48: UK Market Size of Acute-on-chronic liver failure, USD Millions (2018-2030)
  • Table 49: UK market size of Acute-on-chronic liver failure by therapies in USD Million (2018-2030)
  • Table 50: Japan Market Size of Acute-on-chronic liver failure, USD Millions (2018-2030)
  • Table 51: Japan market size of Acute-on-chronic liver failure by therapies in USD Million (2018-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Proposed unifying pathogenesis for different types of acute-on-chronic liver failure
  • Figure 3: The clinical course of cirrhosis
  • Figure 4: Immune dysfunction in ACLF
  • Figure 5: Pathogenesis of organ failure in ACLF
  • Figure 6: Cases of ACLF in the United States (2018-2030)
  • Figure 7: Cases of ACLF by Grades in the United States (2018-2030)
  • Figure 8: Organ failures associated with ACLF in the United States (2018-2030)
  • Figure 9: Potential precipitating events of ACLF in the United States (2018-2030)
  • Figure 10: Cases of ACLF in Germany (2018-2030)
  • Figure 11: Cases of ACLF by Grades in Germany (2018-2030)
  • Figure 12: Organ failures associated with ACLF in Germany (2018-2030)
  • Figure 13: Potential precipitating events of ACLF in Germany (2018-2030)
  • Figure 14: Cases of ACLF in France (2018-2030)
  • Figure 15: Cases of ACLF by Grades in France (2018-2030)
  • Figure 16: Organ failures associated with ACLF in France (2018-2030)
  • Figure 17: Potential precipitating events of ACLF in France (2018-2030)
  • Figure 18: Cases of ACLF in Italy (2018-2030)
  • Figure 19: Cases of ACLF by Grades in Italy (2018-2030)
  • Figure 20: Organ failures associated with ACLF in Italy (2018-2030)
  • Figure 21: Potential precipitating events of ACLF in Italy (2018-2030)
  • Figure 22: Cases of ACLF in Spain (2018-2030)
  • Figure 23: Cases of ACLF by Grades in Spain (2018-2030)
  • Figure 24: Organ failures associated with ACLF in Spain (2018-2030)
  • Figure 25: Potential precipitating events of ACLF in Spain (2018-2030)
  • Figure 26: Cases of ACLF in the UK (2018-2030)
  • Figure 27: Cases of ACLF by Grades in the UK (2018-2030)
  • Figure 28: Organ failures associated with ACLF in the UK (2018-2030)
  • Figure 29: Potential precipitating events of ACLF in the UK (2018-2030)
  • Figure 30: Cases of ACLF in Japan (2018-2030)
  • Figure 31: Cases of ACLF by Grades in Japan (2018-2030)
  • Figure 32: Organ failures associated with ACLF in Japan (2018-2030)
  • Figure 33: Potential precipitating events of ACLF in Japan (2018-2030)
  • Figure 34: Algorithm for management of acute-on-chronic liver failure
  • Figure 35: Patient Journey for ACLF
  • Figure 36: Unmet needs for ACLF
  • Figure 37: 7 Major Market Size of Acute-on-chronic liver failure in USD Million (2018-2030)
  • Figure 38: Market Size of Acute-on-chronic liver failure in the United States, USD Millions (2018-2030)
  • Figure 39: The U.S. market size of Acute-on-chronic liver failure by therapies in USD Million (2018-2030)
  • Figure 40: Market Size of Acute-on-chronic liver failure in Germany, USD Millions (2018-2030)
  • Figure 41: Germany market size of Acute-on-chronic liver failure by therapies in USD Million (2018-2030)
  • Figure 42: Market Size of Acute-on-chronic liver failure in France, USD Millions (2018-2030)
  • Figure 43: France market size of Acute-on-chronic liver failure by therapies in USD Million (2018-2030)
  • Figure 44: Market Size of Acute-on-chronic liver failure in Italy, USD Millions (2018-2030)
  • Figure 45: Italy market size of Acute-on-chronic liver failure by therapies in USD Million (2018-2030)
  • Figure 46: Market Size of Acute-on-chronic liver failure in Spain, USD Millions (2018-2030)
  • Figure 47: Spain market size of Acute-on-chronic liver failure by therapies in USD Million (2018-2030)
  • Figure 48: Market Size of Acute-on-chronic liver failure in the UK, USD Millions (2018-2030)
  • Figure 49: The UK market size of Acute-on-chronic liver failure by therapies in USD Million (2018-2030)
  • Figure 50: Market Size of Acute-on-chronic liver failure in Japan, USD Millions (2018-2030)
  • Figure 51: Japan market size of Acute-on-chronic liver failure by therapies in USD Million (2018-2030)
  • Figure 52: Market drivers for ACLF
  • Figure 53: Market Barriers for ACLF

DelveInsight's 'Acute-On-Chronic Liver Failure (ACLF)-Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the Acute-On-Chronic Liver Failure (ACLF), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Acute-On-Chronic Liver Failure (ACLF) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted ACLF symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Acute-On-Chronic Liver Failure (ACLF) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018-2030

Acute-On-Chronic Liver Failure (ACLF) Disease Understanding and Treatment Algorithm

Acute-on -chronic liver failure (ACLF)Overview

Acute-on -chronic liver failure (ACLF) is a syndrome in patients with chronic liver disease with or without previously diagnosed cirrhosis characterized by acute hepatic decompensation resulting in liver failure (jaundice and prolongation of the international normalized ratio), and one or more extrahepatic organ failures, that is associated with increased risk for mortality within a period of 28 days and up to 3 months from onset.

The natural history of chronic liver disease in a subset of patients is progression to cirrhosis. Cirrhosis has two broad stages. The onset of jaundice, ascites, variceal bleeding, or hepatic encephalopathy heralds the onset of decompensated cirrhosis, whereas the stage where there is an absence of any of these complications is compensated cirrhosis. When viral, drug, alcohol, or ischemic hepatitis, surgery, or sepsis are superimposed upon chronic liver disease with or without either stage of cirrhosis, there is worsening of liver disease that may result in hepatic and extrahepatic organ failure. Furthermore, ACLF is classified into three groups, according to the underlying liver disease ACLF: type A ACLF (patients with underlying non-cirrhotic chronic liver disease), type B ACLF (patients with previously compensated cirrhosis), and C ACLF (patients with previous decompensated cirrhosis). Thus, ACLF is a late stage in the natural history of chronic liver disease with hepatic and extrahepatic organ failure.

Currently, treatment strategies are limited to symptomatic relief and organ support, indicating the necessity for novel biomarkers, drugs, and devices for the management of ACLF. A multidisciplinary management strategy is required to ensure the early detection of organ dysfunction. At the same time, engagement with the liver transplant community is needed to define a new allocation policy for this subset of patients. Methods to further define and characterize ACLF involve additional investigation of the metabolomics profile of patients with ACLF, while G-CSF administration and cell transplantation seem to be novel and promising therapeutic interventions to improve patient outcomes. Furthermore, prospective clinical studies are required to fully elucidate the modifiable factors that predispose patients to ACLF and improve the understanding of this devastating syndrome, while developing a personalized management plan for individual patients based on their clinical and genetic characteristics.

Acute-on -chronic liver failure (ACLF) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Acute-on -chronic liver failure (ACLF) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Acute-on -chronic liver failure (ACLF) market report gives a thorough understanding of ACLF symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides ACLF symptoms of treatment algorithms and treatment guidelines for ACLF symptoms in the US, Europe, and Japan.

Acute-on -chronic liver failure (ACLF) Epidemiology

The epidemiology division's Acute-on -chronic liver failure (ACLF) symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Acute-on -chronic liver failure (ACLF) epidemiology segmented as the Total Cases of Acute-On-Chronic Liver Failure (ACLF), Cases of Acute-On-Chronic Liver Failure (ACLF) by Grades, Organ Failure Associated with Acute-On-Chronic Liver Failure, Potential participating events of Acute-On-Chronic Liver Failure. The report includes the Cases of ACLF in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Acute-on -chronic liver failure (ACLF) Epidemiology

The epidemiology segment also provides the Acute-on -chronic liver failure (ACLF) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total 7MM cases of Acute-on -chronic liver failure (ACLF) were 61,026 in 2020.

Acute-on -chronic liver failure (ACLF) Drug Chapters

The drug chapter segment of the Acute-on -chronic liver failure (ACLF) report encloses the detailed analysis of ACLF marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Acute-on -chronic liver failure (ACLF) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Currently, there is no specific effective treatment available for patients with ACLF, and therefore treatment is based on organ support and treatment of associated complications. When ACLF is associated with a precipitating factor (i.e., bacterial infections, GI bleeding, alcoholism, and drug toxicity), early identification and treatment of the precipitating factor are essential. However, this may not prevent the development or the worsening of the syndrome. In addition, in up to 40% of patients, a precipitating factor may not be identified. Moreover, available data suggest that although the precipitating factor may be the trigger of ACLF, it may not be an essential predictor of prognosis.

Products detail in the report…

Acute-On-Chronic Liver Failure (ACLF) Emerging Drugs

Grifols Therapeutics evaluates the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in acute-on-chronic liver failure (ACLF) subjects. The primary physiological function of albumin results from its contribution to plasma colloid oncotic pressure and transport function. Albumin stabilizes circulating blood volume and is a carrier of hormones, enzymes, medicinal products, and toxins. Other physiological functions include antioxidant properties, free radical scavenging, and capillary membrane integrity.

Products detail in the report…

Acute-On-Chronic Liver Failure (ACLF) Market Outlook

The Acute-On-Chronic Liver Failure (ACLF) market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Acute-On-Chronic Liver Failure (ACLF) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of Acute-On-Chronic Liver Failure (ACLF) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Acute-On-Chronic Liver Failure (ACLF) market in 7MM is expected to change in the study period 2018-2030.

Key Findings

This section includes a glimpse of the Acute-On-Chronic Liver Failure (ACLF) market in 7MM. The market size of ACLF in the seven major markets was found to be USD 71.25 million in 2020, and the market is estimated to increase at a CAGR of 26.77% for the study period (2018-2030).

The United States Market Outlook

This section provides a total of Acute-On-Chronic Liver Failure (ACLF) market size and market size by therapies in the United States.

The United States accounts for the highest ACLF market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Acute-On-Chronic Liver Failure (ACLF) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Acute-On-Chronic Liver Failure (ACLF) market size and market size by therapies in Japan are also mentioned.

Acute-On-Chronic Liver Failure (ACLF) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018-2030. The analysis Acute-On-Chronic Liver Failure (ACLF) market uptake by drugs, patient uptake by therapies, and drug sales.

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

Acute-On-Chronic Liver Failure (ACLF) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Acute-On-Chronic Liver Failure (ACLF) key players involved in developing targeted therapeutics.

Major players include PE-A 5% (Grifols Therapeutics) and Hepastem (Promethera Biosciences) being assessed as potential therapies to be available in the market in the coming future.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Acute-On-Chronic Liver Failure (ACLF) emerging therapies.

Reimbursement Scenario in Acute-On-Chronic Liver Failure (ACLF)

While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient's claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to make sure that the patient receives Social Security Disability benefits as quickly as possible and will help the patient avoid the lengthy disability appeal process

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working Acute-On-Chronic Liver Failure (ACLF) domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapies treatment patterns or Acute-On-Chronic Liver Failure (ACLF) market trends. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Acute-On-Chronic Liver Failure (ACLF) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Acute-On-Chronic Liver Failure (ACLF) explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Acute-On-Chronic Liver Failure (ACLF) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Acute-On-Chronic Liver Failure (ACLF) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Acute-On-Chronic Liver Failure (ACLF) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Acute-On-Chronic Liver Failure (ACLF) market

Report Highlights:

  • In the coming years, Acute-On-Chronic Liver Failure (ACLF) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Acute-On-Chronic Liver Failure (ACLF) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for ACLF. The launch of emerging therapies will significantly impact the Acute-On-Chronic Liver Failure (ACLF) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for ACLF.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Acute-On-Chronic Liver Failure (ACLF) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Acute-On-Chronic Liver Failure (ACLF) Pipeline Analysis
  • Acute-On-Chronic Liver Failure (ACLF) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Acute-On-Chronic Liver Failure (ACLF) Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Acute-On-Chronic Liver Failure (ACLF) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Acute-On-Chronic Liver Failure (ACLF) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Acute-On-Chronic Liver Failure (ACLF) Market share (%) distribution in 2020, and how would it look in 2030?
  • What would be the Acute-On-Chronic Liver Failure (ACLF) total market Size as well as market Size by therapies across the 7MM during the forecast period (2021-2030)?
  • What are the market's key findings across 7MM, and which country will have the largest Acute-On-Chronic Liver Failure (ACLF) market Size during the forecast period (2021-2030)?
  • At what CAGR, the Acute-On-Chronic Liver Failure (ACLF) market is expected to grow by 7MM during the forecast period (2021-2030)?
  • What would be the Acute-On-Chronic Liver Failure (ACLF) market outlook across the 7MM during the forecast period (2021-2030)?
  • What would be the Acute-On-Chronic Liver Failure (ACLF) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Acute-On-Chronic Liver Failure (ACLF)?
  • What is the historical Acute-On-Chronic Liver Failure (ACLF) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Acute-On-Chronic Liver Failure (ACLF) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Acute-On-Chronic Liver Failure (ACLF)?
  • Out of all 7MM countries, which country would have the highest Cases of Acute-On-Chronic Liver Failure (ACLF) population during the forecast period (2021-2030)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2021-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Acute-On-Chronic Liver Failure (ACLF)?
  • What are the current treatment guidelines for treating Acute-On-Chronic Liver Failure (ACLF) in the USA, Europe, and Japan?
  • What are the Acute-On-Chronic Liver Failure (ACLF) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Acute-On-Chronic Liver Failure (ACLF)?
  • How many therapies are developed by each company for the treatment of Acute-On-Chronic Liver Failure (ACLF)?
  • How many emerging therapies are in the mid-stage and late development stages to treat Acute-On-Chronic Liver Failure (ACLF)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute-On-Chronic Liver Failure (ACLF) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute-On-Chronic Liver Failure (ACLF) and their status?
  • What are the key designations that have been granted for the emerging therapies for Acute-On-Chronic Liver Failure (ACLF)?
  • What are the global historical and forecasted markets of Acute-On-Chronic Liver Failure (ACLF)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Acute-On-Chronic Liver Failure (ACLF) market
  • To understand the future market competition in the Acute-On-Chronic Liver Failure (ACLF) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Acute-On-Chronic Liver Failure (ACLF) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Acute-On-Chronic Liver Failure (ACLF) market
  • To understand the future market competition in the Acute-On-Chronic Liver Failure (ACLF) market

Table of Contents

1 Key Insights

2 Report Introduction

3 ACLF Epidemiology Overview at a Glance

  • 3.1 Patient Share Distribution of ACLF in 2018
  • 3.2 Patient Share Distribution of ACLF in 2030

4 ACLF Market Overview at a Glance

  • 4.1 Market Share (%) Distribution of ACLF in 2018
  • 4.2 Market Share (%) Distribution of ACLF in 2030

5 Executive Summary of Acute on Chronic Liver Failure

6 Organizations

7 SWOT Analysis of Acute-on-Chronic Liver Failure

8 Disease Background and Overview

  • 8.1 Introduction
  • 8.2 Heterogeneity of definitions
  • 8.3 Types of ACLF
  • 8.4 Clinical characteristics and pathophysiology
  • 8.5 Diagnosis of ACLF
  • 8.6 ACLF Biomarkers

9 Country-wise Epidemiology of Acute-on-Chronic Liver Failure (ACLF)

  • 9.1 Assumptions and Rationale: 7MM

10 Epidemiology and Patient Population

  • 10.1 Key Findings
  • 10.2 7MM Total Prevalent Patient Population of Acute-on-chronic liver failure
  • 10.3 United States
    • 10.3.1 Cases of Acute-on-chronic liver failure (ACLF) in the United States
    • 10.3.2 Cases of ACLF by Grades in the United States
    • 10.3.3 Organ failures associated with ACLF in the United States
    • 10.3.4 Potential precipitating events of ACLF in the United States
  • 10.4 Germany
    • 10.4.1 Cases of Acute-on-chronic liver failure (ACLF) in Germany
    • 10.4.2 Cases of ACLF by Grades in Germany
    • 10.4.3 Organ failures associated with ACLF in Germany
    • 10.4.4 Potential precipitating events of ACLF in Germany
  • 10.5 France
    • 10.5.1 Cases of Acute-on-chronic liver failure (ACLF) in France
    • 10.5.2 Cases of ACLF by Grades in France
    • 10.5.3 Organ failures associated with ACLF in France
    • 10.5.4 Potential precipitating events of ACLF in France
  • 10.6 Italy
    • 10.6.1 Cases of Acute-on-chronic liver failure (ACLF) in Italy
    • 10.6.2 Cases of ACLF by Grades in Italy
    • 10.6.3 Organ failures associated with ACLF in Italy
    • 10.6.4 Potential precipitating events of ACLF in Italy
  • 10.7 Spain
    • 10.7.1 Cases of Acute-on-chronic liver failure (ACLF) in Spain
    • 10.7.2 Cases of ACLF by Grades in Spain
    • 10.7.3 Organ failures associated with ACLF in Spain
    • 10.7.4 Potential precipitating events of ACLF in Spain
  • 10.8 United Kingdom
    • 10.8.1 Cases of Acute-on-chronic liver failure (ACLF) in the UK
    • 10.8.2 Cases of ACLF by Grades in the UK
    • 10.8.3 Organ failures associated with ACLF in the UK
    • 10.8.4 Potential precipitating events of ACLF in the UK
  • 10.9 Japan
    • 10.9.1 Cases of Acute-on-chronic liver failure (ACLF) in Japan
    • 10.9.2 Cases of ACLF by Grades in Japan
    • 10.9.3 Organ failures associated with ACLF in Japan
    • 10.9.4 Potential precipitating events of ACLF in Japan

11 Treatment

  • 11.1 Guidelines
    • 11.1.1 APASL
    • 11.1.2 EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
  • 11.2 Case Study
    • 11.2.1 Acute-on-chronic liver failure vs. traditional acute decompensation of cirrhosis
  • 11.3 Patient Journey

12 Unmet Needs

13 Emerging Therapies

  • 13.1 Albutein (PE-A 5%): Grifols Therapeutics
    • 13.1.1 Product Description
    • 13.1.2 Clinical Development
      • 13.1.2.1 Clinical trials information
  • 13.2 HepaStem: Promethera Biosciences
    • 13.2.1 Product Description
    • 13.2.2 Other Developmental Activities
    • 13.2.3 Clinical Development
      • 13.2.3.1 Clinical trials information
    • 13.2.4 Safety and Efficacy

14 Other Promising Candidates

  • 14.1 Nitazoxanide (NTZ): GENFIT
    • 14.1.1 Product Description
  • 14.2 TAK-242: Akaza Bioscience
    • 14.2.1 Product Description
    • 14.2.2 Clinical Development
      • 14.2.2.1 Clinical trials information
  • 14.3 APZ2: RHEACELL
    • 14.3.1 Product Description
    • 14.3.2 Clinical Development
  • 14.4 VS-01: Versantis
    • 14.4.1 Product Description
    • 14.4.2 Other Developmental Activities

15 Suspended Products

  • 15.1 Livantra: Martin Pharmaceuticals
    • 15.1.1 Product Description
    • 15.1.2 Other developmental activities
    • 15.1.3 Clinical Development

16 Acute-on-chronic liver failure (ACLF): 7 Major Market Analysis

  • 16.1 Key Findings
  • 15.1 Market Size of Acute-on-chronic liver failure in 7MM
  • 16.2 Market Outlook: 7MM

17 Country-wise Market Analysis: Acute-on-chronic liver failure (ACLF)

  • 15.2 United States
    • 15.2.1 Total Market size of Acute-on-chronic liver failure
    • 15.2.2 Acute-on-chronic liver failure Market Size by Therapies
  • 15.3 EU5 Countries
    • 15.3.1 Germany
      • 15.3.1.1 Total Market size of Acute-on-chronic liver failure
      • 15.3.1.2 Acute-on-chronic liver failure Market Size by Therapies
    • 17.1.1 France
      • 17.1.1.1 Total Market size of Acute-on-chronic liver failure
      • 17.1.1.2 Acute-on-chronic liver failure Market Size by Therapies
    • 17.1.2 Italy
      • 17.1.2.1 Total Market size of Acute-on-chronic liver failure
      • 17.1.2.2 Acute-on-chronic liver failure Market Size by Therapies
    • 17.1.3 Spain
      • 17.1.3.1 Total Market size of Acute-on-chronic liver failure
      • 17.1.3.2 Acute-on-chronic liver failure Market Size by Therapies
    • 17.1.4 United Kingdom
      • 17.1.4.1 Total Market size of Acute-on-chronic liver failure
      • 17.1.4.2 Acute-on-chronic liver failure Market Size by Therapies
  • 17.2 Japan
    • 17.2.1 Total Market size of Acute-on-chronic liver failure
    • 17.2.2 Acute-on-chronic liver failure Market Size by Therapies

18 KOL Views

19 Market Drivers

20 Market Barriers

21 Bibliography

22 Appendix

  • 22.1 Report Methodology

23 DelveInsight Capabilities

24 Disclaimer

25 About DelveInsight

Back to Top
전화 문의
F A Q